Opus Genetics (IRD) CFO awarded 400,000 restricted stock units in Form 4

Rhea-AI Filing Summary

Opus Genetics, Inc. reported an equity award to its Chief Financial Officer, Robert E. Gagnon. On January 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as an acquisition. A footnote explains that this represents a grant of restricted stock units that vest in substantially equal quarterly installments on the anniversary of the grant date over the next 16 quarters, subject to his continuing service. Following this grant, Gagnon beneficially owned 600,000 shares of Opus Genetics common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gagnon Robert E.

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		400,000(1)	A	$0	600,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.

	/s/ Amy Rabourn, by Power of Attorney	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Opus Genetics (IRD) report for January 22, 2026?

Opus Genetics reported that Chief Financial Officer Robert E. Gagnon acquired 400,000 shares of common stock on January 22, 2026, at a reported price of $0 per share, tied to a restricted stock unit grant.

Who is the insider involved in this Opus Genetics (IRD) Form 4 filing?

The filing identifies Robert E. Gagnon as the reporting person. He serves as Chief Financial Officer of Opus Genetics, Inc. and is not listed as a director or 10% owner in this filing.

How many Opus Genetics (IRD) shares does the CFO own after this transaction?

After the reported transaction, Chief Financial Officer Robert E. Gagnon beneficially owned 600,000 shares of Opus Genetics common stock, held in direct ownership.

What are the vesting terms of the restricted stock units granted to the Opus Genetics (IRD) CFO?

The filing states that the restricted stock units vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, and vesting is subject to the CFO’s continuing service.

Was any cash paid for the Opus Genetics (IRD) shares reported in this Form 4?

The transaction in the Form 4 shows the 400,000 common shares were acquired at a reported price of $0 per share, consistent with a restricted stock unit grant rather than an open-market purchase.

Is the Opus Genetics (IRD) CFO’s ownership reported as direct or indirect?

The Form 4 indicates that the CFO’s 600,000 shares of Opus Genetics common stock are held under direct (D) ownership, with no separate entity listed in the nature of indirect beneficial ownership field.